Search

Odanacatib

Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388].

4-O-Demethylpenclomedine

MPT0B640

MPT0B640 was under investigation in clinical trials NCT04526717 for COVID-19 infection and NCT04294875 for locally advanced or metastatic solid malignancies.

ZYCOV-D

The ZYCOV-D vaccine candidate was developed by Cadila Healthcare Ltd. based in India[A219758].

SNS-032

Setiptiline

Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA). In Japan, the company Mochida started its commercialization for the treatment of depression started in 1989.

Cefodizime

Cefodizime is a third generation cephalosporin with a broad spectrum of antibacterial activity.

AVR118

infection and chemotherapeutic drugs employed in the treatment of cancers); for its ability to stimulate the immune system to attack tumor cells (especially those cancer cells that have been damaged by

Recombinant alpha 1-antitrypsin

Alpha 1-antitrypsin is a glycoprotein primarily produced by hepatocytes, and to a lesser extent, immune system cells.

BBV152

BBV152 is a vaccine candidate created by the Indian Council of Medical Research (ICMR).